Core Insights - Sight Sciences, Inc. will report its financial results for Q4 and the full year ended December 31, 2024, on March 5, 2025, after market close [1] - A conference call to discuss the results will take place at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day [1] Company Overview - Sight Sciences is an eyecare technology company focused on developing innovative and interventional solutions to improve patient care and transform treatment paradigms [3] - The company offers the OMNI Surgical System, which is an implant-free glaucoma surgery technology aimed at reducing intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION Surgical Instrument is a bladeless device used in ophthalmic surgeries to excise trabecular meshwork [3] - The TearCare System is cleared in the U.S. for localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, addressing the leading cause of dry eye disease [3]

MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day, in New York, NY. Sight Sciences’ management is scheduled to present on Thursday, February 27, 2025, at 7:15 am PT / 10:15 ...

Core Insights - Sight Sciences, Inc. is an eyecare technology company focused on developing innovative interventional technologies to transform care and improve patients' lives [1][3] - The company will present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day on February 27, 2025 [2] Company Overview - Sight Sciences specializes in minimally invasive or non-invasive solutions targeting prevalent eye diseases, aiming to enhance patient care and replace outdated treatment methods [3] - The OMNI® Surgical System is designed for glaucoma surgery, indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma in the U.S. and CE Marked for specific procedures in Europe [3] - The SION® Surgical Instrument is a bladeless device for excising trabecular meshwork in ophthalmic surgeries [3] - The TearCare® System is cleared in the U.S. for localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, addressing the leading cause of dry eye disease [3]

MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported select preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2024. Select Preliminary Financial Highlights Fourth quarter 2024 total revenue is expected to be in the range of ...

Core Viewpoint - Sight Sciences, Inc. reported preliminary financial highlights for Q4 and full year 2024, indicating a mixed performance with slight revenue growth in Q4 but an overall decline for the year [1][3]. Financial Highlights - Q4 2024 total revenue is expected to be between $18.9 million and $19.1 million, reflecting a 1% increase at the estimated midpoint compared to the same period last year [2]. - Full year 2024 total revenue is projected to be between $79.7 million and $79.9 million, representing a 2% decrease at the estimated midpoint compared to the previous year [3]. - Cash and cash equivalents as of December 31, 2024, were approximately $120 million, up from $118.6 million as of September 30, 2024 [4]. Segment Performance - Surgical Glaucoma revenue for Q4 is expected to be between $18.7 million and $18.8 million, a 9% increase at the estimated midpoint compared to Q4 2023 [5][7]. - Dry Eye revenue for Q4 is expected to be between $0.2 million and $0.3 million, a significant decrease from $1.6 million in the prior year [7]. - Full year Surgical Glaucoma revenue is expected to be between $75.8 million and $75.9 million, a 2% increase at the estimated midpoint compared to the previous year [7]. - Full year Dry Eye revenue is expected to be between $3.9 million and $4.0 million, down from $6.7 million in 2023 [7]. Cash Management - Cash generated in Q4 totaled approximately $1.4 million, a significant improvement compared to cash used of $6.4 million in the same period last year [7]. - Total cash used during the year was approximately $18.1 million, a reduction from $46.9 million in the prior year [7]. - The company aims to achieve cash flow breakeven without raising additional equity capital [7]. Strategic Outlook - The company is focused on effective cash management while investing in long-term value drivers, positioning itself well for 2025 with a strong cash position and differentiated technologies [5]. - The company anticipates continued progress towards establishing equitable reimbursed market access for its TearCare product [5].

The study is the largest to date evaluating clinical outcomes of standalone canaloplasty and trabeculotomy. It analyzes real-world data from the American Academy of Ophthalmology IRIS® Registry and demonstrates sustained intraocular pressure reductions and decreased medication dependenceMENLO PARK, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventiona ...

Budget impact analysis published in the Expert Review of Ophthalmology journalMENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced the results of a Budget Impact Analysis (“BIA”) of the TearCare® System (“TearCare”) for the treatment of MGD-associated dry eye disease (“DED” ...

MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced the results of a Budget Impact Analysis ("BIA") of the TearCare® System ("TearCare") for the treatment of MGD-associated dry eye disease ("DED") in the United States. A BIA estimates the fiscal impact of adopting a new tec ...

MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Piper Sandler 36th Annual Healthcare Conference, in New York, NY. Sight Sciences’ management is scheduled to present on Tuesday, December 3, 2024, at 12:30 pm PT / 3:30 pm ET. Intereste ...

Sight Sciences, Inc. (NASDAQ:SGHT) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matt Link - Chief Commercial Officer Conference Call Participants Macauley Kilbane - William Blair Phil Dantoin - Piper Sandler Nelson Cox - Lake Street Capital Markets Tom Stephan - Stifel Operator Thank you for standing by. My name is Janine, I will be your c ...